Andrii Balia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrii Balia has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Castillo
Department of Molecular & Physiology, University of Michigan, Ann Arbor, MI, USA
9 shared publications - Elizabeth C. McCulla
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Hannah Noelle Bell
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Indrani Talukder
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Jianping He
Department of Biological Sciences, University of Notre Dame, Notre Dame, USA
9 shared publications - Joao A. Paulo
Department of Cell Biology, Harvard Medical School, Boston, MA, USA
9 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S3 shows selenoprotein expression validations upon selenium supplementation and identifies RSL3 targets through AP-MS proteomic analysis.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S3 shows selenoprotein expression validations upon selenium supplementation and identifies RSL3 targets through AP-MS proteomic analysis.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (15) , 2788-2804
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Ferroptosis is a nonapoptotic form of cell death driven by iron-dependent lipid peroxide accumulation. Colorectal cancer cells feature elevated intracellular iron and reactive oxygen species that heighten ferroptosis sensitivity. The ferroptosis inducer (S)-RSL3 [(1S,3R)-RSL3] is widely described as a selective inhibitor of the selenocysteine-containing enzyme (selenoprotein) glutathione peroxidase 4 (GPX4), which detoxifies lipid peroxides using glutathione. However, through chemical controls using the (R) stereoisomer of RSL3 [(1R,3R)-RSL3] that does not bind GPX4, combined with inducible genetic knockdowns of GPX4 in colorectal cancer cell lines, we revealed in this study that GPX4 dependency does not always align with (S)-RSL3 sensitivity, thereby questioning the current characterization of GPX4 as the primary target of (S)-RSL3. Affinity pull-down mass spectrometry with modified (S)-RSL3 probes identified multiple selenoprotein targets, indicating broad selenoprotein inhibition. Further investigation of the therapeutic potential of broadly disrupting the selenoproteome as a therapeutic strategy in colorectal cancer showed that the selenoprotein inhibitor auranofin, an FDA-approved gold salt, chemically induced oxidative cell death and ferroptosis in colorectal cancer models in vitro and in vivo. Similarly, genetic perturbation of ALKBH8, a tRNA-selenocysteine methyltransferase required for selenoprotein translation, suppressed colorectal cancer growth. In summary, these findings recharacterize the mechanism of (S)-RSL3 beyond GPX4 inhibition and establish selenoproteome disruption as a colorectal cancer therapeutic strategy. Significance: Chemoproteomic profiling reveals that RSL3 functions through pan-selenoprotein inhibition beyond GPX4 and identifies ALKBH8, a tRNA-selenocysteine methyltransferase essential for selenoprotein translation, as a therapeutic target to disrupt redox balance in colorectal cancer. See related commentary by Short, p. 2775
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (15) , 2788-2804
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Ferroptosis is a nonapoptotic form of cell death driven by iron-dependent lipid peroxide accumulation. Colorectal cancer cells feature elevated intracellular iron and reactive oxygen species that heighten ferroptosis sensitivity. The ferroptosis inducer (S)-RSL3 [(1S,3R)-RSL3] is widely described as a selective inhibitor of the selenocysteine-containing enzyme (selenoprotein) glutathione peroxidase 4 (GPX4), which detoxifies lipid peroxides using glutathione. However, through chemical controls using the (R) stereoisomer of RSL3 [(1R,3R)-RSL3] that does not bind GPX4, combined with inducible genetic knockdowns of GPX4 in colorectal cancer cell lines, we revealed in this study that GPX4 dependency does not always align with (S)-RSL3 sensitivity, thereby questioning the current characterization of GPX4 as the primary target of (S)-RSL3. Affinity pull-down mass spectrometry with modified (S)-RSL3 probes identified multiple selenoprotein targets, indicating broad selenoprotein inhibition. Further investigation of the therapeutic potential of broadly disrupting the selenoproteome as a therapeutic strategy in colorectal cancer showed that the selenoprotein inhibitor auranofin, an FDA-approved gold salt, chemically induced oxidative cell death and ferroptosis in colorectal cancer models in vitro and in vivo. Similarly, genetic perturbation of ALKBH8, a tRNA-selenocysteine methyltransferase required for selenoprotein translation, suppressed colorectal cancer growth. In summary, these findings recharacterize the mechanism of (S)-RSL3 beyond GPX4 inhibition and establish selenoproteome disruption as a colorectal cancer therapeutic strategy. Significance: Chemoproteomic profiling reveals that RSL3 functions through pan-selenoprotein inhibition beyond GPX4 and identifies ALKBH8, a tRNA-selenocysteine methyltransferase essential for selenoprotein translation, as a therapeutic target to disrupt redox balance in colorectal cancer. See related commentary by Short, p. 2775
- 30 September 2024
- Published by Kundiiev Institute of Occupational Health of National Academy of Medical Sciences of Ukraine in Ukrainian Journal of Occupational Health
- Vol. 2024 (3) , 176-183
Potential risk assessment in occupational exposure to highly dispersive materials
Potential Risk Assessment in Occupational Exposure to Highly Dispersive Materials: ISSN 2223-6775 Ukrainian journal of occupational health Vol.20, No 3, 2024doi xxxxxx Potential Risk Assessment in Occupational Exposure to Highly Dispersive Materials Beliuha O.G. 1), Demetska O.V. 2), Movchan V.O. 1), Balia A.H. 3) 1) SI Kundiev Institu
- 30 September 2024
- Published by Kundiiev Institute of Occupational Health of National Academy of Medical Sciences of Ukraine in Ukrainian Journal of Occupational Health
- Vol. 2024 (3) , 176-183
Potential risk assessment in occupational exposure to highly dispersive materials
Potential Risk Assessment in Occupational Exposure to Highly Dispersive Materials: ISSN 2223-6775 Ukrainian journal of occupational health Vol.20, No 3, 2024doi xxxxxx Potential Risk Assessment in Occupational Exposure to Highly Dispersive Materials Beliuha O.G. 1), Demetska O.V. 2), Movchan V.O. 1), Balia A.H. 3) 1) SI Kundiev Institu